10-Q: ZyVersa Faces Nasdaq Delisting, Seeks New Capital

ZyVersa Therapeutics reports significant losses and a going concern warning, with its common stock delisted from Nasdaq and now trading on OTCQB.

Summary

• ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of approximately $4.5 million for the six months ended June 30, 2025, an improvement from $5.6 million in the prior year period.
• Cash reserves significantly declined to $72,086 as of June 30, 2025, down from $1,530,924 at December 31, 2024.
• The company has an accumulated deficit of approximately $117.1 million as of June 30, 2025, and a working capital deficiency of $12.1 million.
• Research and development expenses decreased by 45.3% to $0.7 million for the six months ended June 30, 2025, primarily due to lower CRO fees and consultant costs.
• General and administrative expenses decreased by 19.2% to $3.5 million for the six months ended June 30, 2025, driven by lower insurance premiums, marketing, and professional fees.
• The company's common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025, and began trading on the OTCQB Venture Market on July 28, 2025.
• ZyVersa entered into an Equity Purchase Agreement for up to $10.0 million in common stock and completed a private placement of warrants for approximately $2.0 million in gross proceeds.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to critical liquidity issues, a going concern warning, and the significant blow of Nasdaq delisting. While there are efforts to raise capital and some cost reductions, the overall financial health and market standing are severely compromised.

Positives

• Net loss for the six months ended June 30, 2025, decreased to $4.5 million from $5.6 million in the prior year period.
• Cash used in operating activities decreased to $3.3 million for the six months ended June 30, 2025, from $5.7 million in the prior year period.
• Research and development expenses decreased by 45.3%, indicating cost management in clinical programs.
• General and administrative expenses decreased by 19.2%, reflecting efforts to reduce overhead costs.
• Secured an Equity Purchase Agreement for up to $10.0 million and completed a private placement of warrants for $2.0 million, providing access to potential capital.

Negatives

• Cash balance significantly declined to $72,086 as of June 30, 2025, indicating severe liquidity constraints.
• Working capital deficiency worsened to $12.1 million as of June 30, 2025.
• The company has an accumulated deficit of $117.1 million and has not yet achieved profitability.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year.
• Common stock was delisted from The Nasdaq Capital Market on July 17, 2025, and now trades on the OTCQB Venture Market, impacting marketability and investor confidence.
• Interest expense increased significantly due to interest charged by a vendor for outstanding amounts owed.
• Disputed vendor invoices totaling $1,123,973 remain unaccrued by the company, posing a potential liability.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant operating losses, negative cash flows, and limited cash reserves.
• Inability to raise additional funds through equity or debt financing on acceptable terms, or at all, which would negatively impact business strategy and development initiatives.
• The common stock has been delisted from Nasdaq and now trades on the OTCQB Venture Market, which may result in a very limited market, difficulty selling shares, and adverse effects on trading price.
• The common stock could become subject to SEC's penny stock rules if net tangible assets fall below $2.0 million, further limiting marketability.
• Uncertainty regarding the success, timing, and costs of clinical trials for product candidates (VAR 200 and IC 100), and whether regulatory approval will be obtained.
• Reliance on a single vendor for 56% of accounts payable related to critical research and development activities, posing concentration risk.
• Potential adverse impact from changes in tax laws and regulations, such as the Tax Reform Act of 2025, on the effective tax rate and financial condition.
• Disputed vendor invoices represent a potential financial liability not fully accrued by the company.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it progresses development of its drug candidates, VAR 200 and IC 100, prepares regulatory submissions, and begins manufacturing for clinical trials. Additional financing will be required to support continuing operations, and there is no assurance that such financing will be available on acceptable terms or that the company will achieve profitability.

Management Comments

• Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all.
• The company expects its research and development and general and administrative expenses to continue to increase, requiring significant product revenues to achieve profitability.

Industry Context

ZyVersa operates in the highly capital-intensive and high-risk clinical-stage biopharmaceutical industry, characterized by long development cycles, significant R&D expenditures, and reliance on external funding. The company's current financial state, including substantial losses, limited cash, and a going concern warning, is not uncommon for early-stage biotech firms that have not yet achieved significant clinical milestones or commercialization. The delisting from Nasdaq to OTCQB is a severe blow, significantly reducing visibility and liquidity, which is a major challenge for attracting institutional investment and retaining shareholder value in this competitive sector.

Comparison to Industry Standards

• Unlike more established biopharmaceutical companies that generate revenue from approved products (e.g., Pfizer, Johnson & Johnson), ZyVersa is a clinical-stage company with no revenue to date, aligning with the early-stage profile of many biotech startups.
• The significant accumulated deficit of $117.1 million and ongoing net losses are typical for companies in the drug development phase, similar to other pre-revenue biotechs like those developing novel therapies for rare diseases (e.g., early-stage Vertex Pharmaceuticals in cystic fibrosis or Sarepta Therapeutics in Duchenne muscular dystrophy before product approval).
• The cash position of $72,086 and working capital deficiency of $12.1 million are critically low compared to industry peers that typically maintain several quarters to years of cash runway to fund extensive clinical trials (e.g., a typical Phase 2 trial can cost tens of millions of dollars).
• The delisting from Nasdaq to OTCQB is a significant deviation from industry standards for publicly traded biopharmaceutical companies, which typically strive to maintain listing on major exchanges like Nasdaq or NYSE for credibility, liquidity, and access to broader investor bases. This move places ZyVersa in a less favorable position compared to peers that successfully maintain their listings while advancing their pipelines.
• The reliance on a single vendor for 56% of accounts payable related to R&D is a concentration risk that is generally mitigated by larger, more diversified biopharma companies through multiple vendor relationships.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises.
• Shareholders will experience reduced liquidity and marketability of their common stock due to the delisting from Nasdaq and trading on the OTCQB Venture Market.
• Employees and consultants may face uncertainty regarding job security and compensation due to the company's going concern status and limited cash reserves.
• Creditors, particularly the vendor with disputed invoices, face uncertainty regarding the full settlement of outstanding amounts.
• Potential future customers and partners may view the company with increased skepticism due to its financial instability and delisting.

Next Steps

• Progress development of VAR 200 and IC 100 drug candidates.
• Prepare and file regulatory submissions for product candidates.
• Begin manufacturing product candidates for clinical trials.
• Hire additional research and development, finance, and general and administrative personnel.
• Protect and defend intellectual property.
• Meet the requirements of being a public company (despite OTCQB listing).
• Generate significant product revenues to achieve profitability (long-term goal).
• Raise additional funds through public or private equity or debt financings or other sources (e.g., government grants, collaborations).

Key Dates

Recommendation

The company faces severe financial distress, evidenced by critically low cash reserves ($72,086), a worsening working capital deficiency ($12.1 million), and an explicit 'going concern' warning. The delisting from Nasdaq to the OTCQB Venture Market significantly impairs liquidity, market visibility, and the ability to attract institutional investment. While the company is pursuing capital raises, the terms may be highly dilutive, and there's no assurance of securing sufficient funds. The fundamental business model of a pre-revenue biopharmaceutical company is inherently risky, and these financial and operational challenges amplify that risk to an extreme degree, making the stock a high-risk, low-probability investment.

Keywords

Biopharmaceutical, Clinical Stage, Renal Disease, Inflammatory Disease, FSGS, Obesity, VAR 200, IC 100, Nasdaq Delisting, OTCQB, Going Concern, SEC Filing, 10-Q, Drug Development, Biotech